Myelofibrosis - Pipeline Insight, 2021
This report can be delivered to the clients within 72 hours
DelveInsight’s, “Myelofibrosis - Pipeline Insight, 2021,” report provides comprehensive insights about 45+ companies and 45+ pipeline drugs in Myelofibrosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Myelofibrosis: Overview
Myelofibrosis is a rare disorder in which abnormal blood cells and fibers build up in the bone marrow. It is considered as a form of chronic leukemia. When myelofibrosis occurs on its own, it is called as primary myelofibrosis. If the disease occur as the result of a separate disease, it is known as secondary myelofibrosis. One characteristic of myelofibrosis is the overproduction of giant cells called megakaryocytes. Risk factors for myelofibrosis include exposure to ionizing radiation or to petrochemicals, such as benzene or toluene. The diagnosis of myelofibrosis include physical examination, blood tests, imaging tests, bone marrow examination, and gene tests to look for gene mutations in blood cells that are associated with myelofibrosis. Myelofibrosis treatment usually depends on the types of symptoms. Jakafi (ruxolitinib) is the first drug approved by the Food and Drug Administration for the treatment of intermediate or high-risk myelofibrosis.
'Myelofibrosis - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Myelofibrosis pipeline landscape is provided which includes the disease overview and Myelofibrosis treatment guidelines. The assessment part of the report embraces, in depth Myelofibrosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Myelofibrosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Myelofibrosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Myelofibrosis Emerging Drugs
Further product details are provided in the report……..
Myelofibrosis: Therapeutic Assessment
This segment of the report provides insights about the different Myelofibrosis drugs segregated based on following parameters that define the scope of the report, such as:
Myelofibrosis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Myelofibrosis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Myelofibrosis drugs.
Myelofibrosis Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Myelofibrosis - Pipeline Insight, 2021,” report provides comprehensive insights about 45+ companies and 45+ pipeline drugs in Myelofibrosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Myelofibrosis: Overview
Myelofibrosis is a rare disorder in which abnormal blood cells and fibers build up in the bone marrow. It is considered as a form of chronic leukemia. When myelofibrosis occurs on its own, it is called as primary myelofibrosis. If the disease occur as the result of a separate disease, it is known as secondary myelofibrosis. One characteristic of myelofibrosis is the overproduction of giant cells called megakaryocytes. Risk factors for myelofibrosis include exposure to ionizing radiation or to petrochemicals, such as benzene or toluene. The diagnosis of myelofibrosis include physical examination, blood tests, imaging tests, bone marrow examination, and gene tests to look for gene mutations in blood cells that are associated with myelofibrosis. Myelofibrosis treatment usually depends on the types of symptoms. Jakafi (ruxolitinib) is the first drug approved by the Food and Drug Administration for the treatment of intermediate or high-risk myelofibrosis.
'Myelofibrosis - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Myelofibrosis pipeline landscape is provided which includes the disease overview and Myelofibrosis treatment guidelines. The assessment part of the report embraces, in depth Myelofibrosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Myelofibrosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Myelofibrosis R&D. The therapies under development are focused on novel approaches to treat/improve Myelofibrosis.
This segment of the Myelofibrosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Myelofibrosis Emerging Drugs
- Parsaclisib: Incyte Corporation
- KER-050: Keros Therapeutics
Further product details are provided in the report……..
Myelofibrosis: Therapeutic Assessment
This segment of the report provides insights about the different Myelofibrosis drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Myelofibrosis
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravitreal
- Subretinal
- Topical
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Myelofibrosis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Myelofibrosis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Myelofibrosis drugs.
Myelofibrosis Report Insights
- Myelofibrosis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Myelofibrosis drugs?
- How many Myelofibrosis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Myelofibrosis?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Myelofibrosis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Myelofibrosis and their status?
- What are the key designations that have been granted to the emerging drugs?
- Incyte Corporation
- Keros Therapeutics
- Karyopharm Therapeutics
- Celgene Corporation
- PharmaEssentia
- Novartis
- Secura Bio
- Pharmaxis
- Novartis Oncology
- AstraZeneca
- Cellenkos
- Jacobio Pharmaceuticals
- Ohm oncology
- Parsaclisib
- KER-050
- Selinexor
- Lenalidomide
- Ropeginterferonum alfa-2b
- Panobinostat
- PXS-5505
- Spartalizumab
- Selumetinib
- CK-0804
- JAB-8263
- OHM-581
Introduction
Executive Summary
Myelofibrosis: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Myelofibrosis – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Parsaclisib: Incyte Corporation
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Mid Stage Products (Phase II)
Comparative Analysis
KER-050: Keros Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I/II)
Comparative Analysis
PXS-5505: Pharmaxis
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Preclinical and Discovery Stage Products
Comparative Analysis
CK-0804: Cellenkos
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Myelofibrosis Key Companies
Myelofibrosis Key Products
Myelofibrosis- Unmet Needs
Myelofibrosis- Market Drivers and Barriers
Myelofibrosis- Future Perspectives and Conclusion
Myelofibrosis Analyst Views
Appendix
Executive Summary
Myelofibrosis: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Myelofibrosis – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Parsaclisib: Incyte Corporation
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Mid Stage Products (Phase II)
Comparative Analysis
KER-050: Keros Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I/II)
Comparative Analysis
PXS-5505: Pharmaxis
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Preclinical and Discovery Stage Products
Comparative Analysis
CK-0804: Cellenkos
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Myelofibrosis Key Companies
Myelofibrosis Key Products
Myelofibrosis- Unmet Needs
Myelofibrosis- Market Drivers and Barriers
Myelofibrosis- Future Perspectives and Conclusion
Myelofibrosis Analyst Views
Appendix
LIST OF TABLES
Table 1 Total Products for Myelofibrosis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Myelofibrosis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Myelofibrosis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Myelofibrosis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
